Insulin suppresses glucose output from the liver via Akt activation; however, which substrate of Akt plays the major role in transducing this effect is unclear. We tested the postnatal expression of Aktunresponsive, constitutively active mutants of three major Akt substrates widely considered to regulate glucose metabolism [i.e., FoxO1, PGC1a, and glycogen synthase kinase-3b (GSK3b)] using adenoviral gene delivery to the mouse liver. We performed physiological hyperinsulinemiceuglycemic clamp studies using these mice under awake and nonrestrained conditions with blood sampling via an arterial catheter. Hepatic expression of constitutively active FoxO1 induced significant hepatic and systemic insulin resistance. However, neither the expression of constitutively active PGC1a nor that of GSK3b significantly changed insulin sensitivity. Simultaneous expression of all three mutants together induced no further insulin resistance compared with that of the FoxO1 mutant. The glycogen content in the liver was significantly reduced by constitutively active GSK3b expression. In cultured hepatocytes, constitutively active PGC1a induced markedly stronger transcriptional enhancement of gluconeogenic key enzymes than did constitutively active FoxO1. From these results, we conclude that FoxO1 has the most prominent role in transducing insulin's effect downstream from Akt to suppress hepatic glucose output, involving mechanisms independent of the transcriptional regulation of key gluconeogenic enzymes. (Endocrinology 158: 2659(Endocrinology 158: -2671(Endocrinology 158: , 2017 
Insulin suppresses glucose output from the liver via Akt activation; however, which substrate of Akt plays the major role in transducing this effect is unclear. We tested the postnatal expression of Aktunresponsive, constitutively active mutants of three major Akt substrates widely considered to regulate glucose metabolism [i.e., FoxO1, PGC1a, and glycogen synthase kinase-3b (GSK3b)] using adenoviral gene delivery to the mouse liver. We performed physiological hyperinsulinemiceuglycemic clamp studies using these mice under awake and nonrestrained conditions with blood sampling via an arterial catheter. Hepatic expression of constitutively active FoxO1 induced significant hepatic and systemic insulin resistance. However, neither the expression of constitutively active PGC1a nor that of GSK3b significantly changed insulin sensitivity. Simultaneous expression of all three mutants together induced no further insulin resistance compared with that of the FoxO1 mutant. The glycogen content in the liver was significantly reduced by constitutively active GSK3b expression. In cultured hepatocytes, constitutively active PGC1a induced markedly stronger transcriptional enhancement of gluconeogenic key enzymes than did constitutively active FoxO1. From these results, we conclude that FoxO1 has the most prominent role in transducing insulin's effect downstream from Akt to suppress hepatic glucose output, involving mechanisms independent of the transcriptional regulation of key gluconeogenic enzymes. (Endocrinology 158: 2659-2671, 2017) I nsulin lowers blood glucose levels by suppressing hepatic glucose output and enhancing peripheral glucose uptake. When the blood concentration of insulin increases, hepatic glucose output decreases via suppression of gluconeogenesis and glycogenolysis and enhancement of glycolysis and glycogenesis. In muscle and adipose tissue, insulin recruits glucose transporter type 4 to the plasma membrane, from which glucose enters cells in a concentration-dependent manner. Akt is regarded as the most important signal transducer of insulin in both liver and glucose transporter type 4-dependent tissues. Overexpression of constitutively active Akt in muscleand adipose tissue-derived cells induces glucose uptake, even without insulin stimulation (1, 2) . We, and other groups, have shown that overexpression of constitutively active Akt in the mouse liver results in hypoglycemia (3, 4) . Activation of Akt reportedly suppresses hepatic gluconeogenesis via direct phosphorylation of substrates, including FoxO1 (5), PGC1a (4) , and others (6) (7) (8) (9) . Activation of Akt reportedly enhances glycogen synthesis via direct phosphorylation and inhibition of glycogen synthase kinase-3 (GSK3), which, in the dephosphorylated state, inactivates glycogen synthase (10) . Akt also reportedly enhances glycolysis via transcriptional enhancement of glycolytic enzymes (3, 11) . Deletions of hepatic Akt1 and Akt2 reportedly induce hyperglycemia and insulin resistance (12) . Therefore, hepatic Akt activation by insulin is responsible for multiple pathways involved in lowering hepatic glucose output.
However, the relative importance of each Akt substrate in the liver for glucose metabolism has not been fully clarified (13, 14) . Regarding FoxO1, genetic deletion (15) and postnatal constitutive overactivation (16) of this protein in the liver have both been reported to, paradoxically, lower blood glucose and enhance insulin sensitivity. Regarding PGC1a, although direct phosphorylation of Akt at Ser570 was reported to result in inhibition of this transcription coactivator and a synergistic effect with FoxO1 was presumed (4, 17) , no in vivo synergistic effect on glucose metabolism has been demonstrated, to the best of our knowledge. Regarding GSK3b, experiments involving pharmacological inhibition (18, 19) and genetic models (20) (21) (22) obtained contradictory results. All three of these Akt substrates (i.e., FoxO1, PGC1a, and GSK3b) have the potential to blunt insulin's glucose-lowering effect; however, no comparisons or synergies among them have been reported. In the present study, we tested the expression of Akt-unresponsive, constitutively active mutants of FoxO1, PGC1a, and GSK3b in the short term in the mouse liver, separately and together. We also investigated which Akt substrate has the strongest influence on insulin sensitivity. Finally, we examined, using insulin clamp studies with the mice under awake and nonrestrained conditions, whether synergistic effects occurred.
Research Design and Methods

Adenoviral vectors
Complete complementary DNA of mouse FoxO1, PGC1a, and GSK3b were amplified by polymerase chain reaction (PCR) from a complementary DNA library of mouse liver with primer sets based on reported sequences. Alanine mutations at specific sites were induced by PCR-based mutagenesis. The primers used to introduce mutations are presented in Supplemental Table 1 . We introduced a restriction site, along with alanine mutations by PCR, except in the case of GSK3b-S9A, and ligated two fragments using that restriction site. All the sequences were confirmed by bidirectional sequencing. Generation, purification, and titration of adenoviruses have been previously described (23) .
Animals
The Institutional Animal Care and Use Committee at Saitama Medical University reviewed and approved all study protocols. C57Bl/6 male mice (Tokyo Laboratory Animals Science, Tokyo, Japan) aged 10 to 12 weeks old were housed in individual cages, with a standard light/dark cycle and given normal chow.
Surgery and vector injection
Catheter implantation was performed 7 days before the clamp and the basal tracer experiments using a stereo microscope with minimal invasion; mice were anesthetized with isoflurane. The left common carotid artery was exposed medially to the sternocleidomastoid muscle, separated from the vagus nerve and the jugular vein in situ, distally ligated, and then catheterized using the Mouse Jugular Catheter (model no. 7700; ALZET, Cupertino, CA) for sampling. The right jugular vein was exposed, distally ligated, and catheterized using MicroRenathane MRE025 (Braintree Scientific, Braintree, MA) for infusion. The free ends of the catheters were tunneled under the skin to the back of the neck. Adenoviral vector 5 3 10 8 plaqueforming units (PFUs) were injected via the venous catheter, and the two catheters were filled with heparinized saline and sealed. The catheters were stored under the skin of the back. More than 90% of the mice had had .90% recovery of body weight by day 7, and arterial blood could be sampled from the catheter in approximately 70% of the mice, which were thus used for the clamp study.
Hyperinsulinemic euglycemic clamp
The clamp study was performed under conscious and unrestrained conditions, as described. Fasting of the mice began at 6 AM [time (t) = 2300 minutes]. At 8:30 AM, we placed the mice in a restrainer and extracted the free ends of the catheters and connected them to PE20 tubes (Instech, Plymouth Meeting, PA), which were then connected to a dual-channel swivel (model no. 375/D/22QM; Instech). After establishing the connection, the mice were returned to a cage in which they were able to move freely. At 9 AM (t= 2120 minutes), we started bolus priming of 2.5 mCi, followed by a 0.05 mCi/min infusion of 3-[ 3 H]-glucose (catalog no. ART0124; Muromachi Yakuhin, Tokyo, Japan); this was maintained for 2 hours as the basal period. A pancreatic insulin clamp with priming of 15 mU/kg, followed by infusion of 1.5 mU/kg/min human insulin (catalog no. I9278; SigmaAldrich, St. Louis, MO) mixed with 3 mg/kg/min somatostatin (catalog no. H1490; Bachem, Bubendorf, Switzerland), was then initiated at t = 0 and lasted for 2 hours. During this clamp period, a 20% glucose solution was infused at a variable rate to maintain the plasma glucose concentrations within the range of 80 to 110 mg/dL. The glucose infusion rate was fixed to 0.33 mg/min for all the mice during the first 30 minutes and then modified as needed thereafter. The blood glucose concentrations were measured at t = 2 120, 2 60, 2 30, 2 15, and 0 minutes and then every 10 minutes from t = 30 to 120 minutes. Blood samples for determination of 3-[
3 H]-glucose-specific activity were obtained at t = 230, 215, 0, 80, 90, 100, 110, and 120 minutes, centrifuged at 3000 rpm for 1 minute. The plasma was then stored, deproteinized with Ba(OH) 2 and ZnSO 4 , and finally dried. Red blood cells were returned to the mice to prevent anemia. Endogenous glucose production (EGP) and the rate of glucose disappearance (Rd) were calculated, as reported previously (24) . At t = 120 minutes, hematocrit was confirmed to be .40%, and the mice were euthanized by isoflurane inhalation and cervical subluxation. The tissues were snap-frozen using liquid nitrogen-cooled metal clamps and stored at 280°C. The numbers of mice in which the clamp study was completed were 21 for LacZ (Z), 7 for FoxO1-T24A-S253A-S316A (F), 11 for PGC1a-S570A (P), 6 for GSK3b-S9A (G), and 7 for coexpression of all three mutants (F+P+G).
Basal tracer study with 24-hour fasting
The mice were fasted for 22 hours, and the bolus, followed by continuous infusion of 3-[ 3 H]-glucose for 2 hours, was executed under nonrestrained, unanesthetized conditions, just as in the clamp study. Arterial blood was sampled at t = 230, 215, and 0 minutes, and the blood glucose levels and tracer concentrations were measured again as in the clamp study.
Cell cultures
H4IIE cells (ATCC, Manassas, VA) were cultured using Eagle minimum essential medium (Sigma-Aldrich) containing 10% fetal calf serum, 1 mM sodium pyruvate, and antibiotics. Next, 6 3 10 5 cells per well were plated onto 12-well culture plates; 18 hours later, the adenoviral vectors were infected at a multiplicity of infection (MOI) of 10. For the group with coexpression of the three substrate mutants, each vector was infected at an MOI of 3.3. Serum starvation was performed 30 hours after infection. At 47 hours after infection, the cells were stimulated with or without 100 nM insulin for 1 hour and then sampled. All H4IIE experiments were performed with three wells of cells for each group.
Mouse primary hepatocytes
Hepatocytes were isolated from 10-to 12-week-old C57Bl/6 mice using the two-step collagenase digestion method (25) . The mouse was euthanized with isoflurane, perfused from the inferior vena cava, and drained from the portal vein. More than 90% of isolated cells did not absorb trypan blue after the isolation step. Next, 3 3 10 5 cells per well suspended in plating medium (Williams E medium with 10% fetal calf serum, 100 nM dexamethasone, 2 mM L-glutamine, 1% nonessential amino acids, and antibiotics) were plated onto collagen-coated 12-well culture plates. Six hours after plating, the medium was changed to culture medium (Williams E medium with 10 nM dexamethasone, 2 mM L-glutamine, 1% nonessential amino acids, and antibiotics). Eighteen hours later, the cells were infected with adenoviral vectors at an MOI of 3. For the group with coexpression of all three substrate mutants, infection with each vector was performed at an MOI of 1. At 47 hours after infection, the cells were stimulated with or without 100 nM insulin for 1 hour and then sampled. All primary hepatocyte experiments were performed with three wells of cells for each group.
Western blots and measurement of glycogen and triglyceride content
The frozen tissues were sonicated in lysis buffer, as previously described (26) . Protein concentrations were measured using a BCA Protein Assay Kit (Pierce Biotechnology, Thermo Fisher Scientific Life Sciences, Waltham, MA) and standardized. Cultured cells were directly suspended in Laemmli buffer. Immunoblots were performed using antibodies against b-actin (catalog no. A2066; Sigma-Aldrich), FoxO1 (catalog no. 2880; Cell Signaling Technology, Danvers, MA), PGC1a (catalog no. AB3242; EMD Millipore, Billerica, MA), GSK3b (catalog no. 9315; Cell Signaling Technology), Akt (catalog no. 4691; Cell Signaling Technology), pThr308-Akt (catalog no. 2965; Cell Signaling Technology), and pSer473-Akt (catalog no. 4060; Cell Signaling Technology), and the bands were detected using enhanced chemiluminescence (GE Healthcare, Little Chalfont, UK). Band quantitation was performed using ImageJ software (National Institutes of Health, Bethesda, MD). Hepatic glycogen and triglyceride content were measured as described previously (3).
Quantitative PCR
Total RNA was isolated using an RNeasy Mini Kit (Qiagen, Hilden, Germany), quantified using a NanoDrop 1000 (NanoDrop Products; Thermo Fisher Scientific Life Sciences), standardized and reverse transcribed using SuperScript III (Life Technologies; Thermo Fisher Scientific Life Sciences). Quantitative PCRs were run using ABI PRISM model 7000 (Applied Biosystems; Thermo Fisher Scientific Life Sciences). TaqMan 
Statistical analysis
Data are presented as the mean 6 standard error of the mean. Comparisons among groups were performed with oneway analysis of variance (ANOVA), followed by Dunnett multiple comparison tests in the in vivo studies, using the LacZ group as the control except for mRNA in hepatic G6Pase and the PGC1a group as the control in Supplemental Fig. 2 . Twoway ANOVA, followed by Tukey multiple comparison tests, were used for the data shown in all other figures. In some analyses, variances among groups were significantly different using the F-test but not significantly different after logarithmic transformation, such that ANOVA and multiple comparisons were performed using logarithmically transformed values.
Results
Effects of hepatic expressions of three Akt-substrate mutants on insulin sensitivity
To investigate whether, and how much, Akt substrates affected insulin sensitivity and blood glucose levels, we tested the expression of Akt-unresponsive, constitutively active mutants of three Akt substrates (i.e., FoxO1-T24A-S253A-S316A, PGC1a-S570A, and GSK3b-S9A) in the livers of mice using adenoviral gene delivery. We then performed a physiological hyperinsulinemic-euglycemic clamp study with the mice under awake and nonrestrained conditions. We implanted arterial and venous catheters for blood sampling and infusion, respectively. Next, 5 3 10 8 PFU of the vectors was injected just after catheter implantation. We also created a group of mice in which all three Akt substrate-mutant vectors were injected at a dose of 1.7 3 10 8 PFU each (F+P+G group). The hepatic expression of the mutants on day 7 was confirmed by immunoblotting [ Fig. 1(a) ]. The fold increases in protein expression compared with the endogenous level with a single viral injection were 5.4 6 0.4 for FoxO1-T24A-S253A-S316A, 8.1 6 2.3 for PGC1a-S570A, and 10.4 6 1.1 for GSK3b-S9A. The fold increases in protein expression with the triple viral injections ere 2.3 6 0.8 for FoxO1-T24A-S253A-S316A, 2.9 6 1.1 for PGC1a-S570A, and 4.3 6 1.8 for GSK3b-S9A. No overexpression of the mutants was observed in other insulin-sensitive tissues (Supplemental Fig. 1 ). The mice's body weight had recovered by .95% by day 7 without differences among the groups [ Fig. 1(b) ]. However, the body weight changes during these 7 days were significantly greater in the F group [ Fig. 1(c) ]. The epididymal fat was significantly heavier in the F+P+G group [ Fig. 1(d) ]. After 5 hours of fasting, the arterial blood glucose levels did not differ significantly among the groups [ Fig. 1(e) ]. However, plasma insulin concentrations were significantly greater in the F and F+P+G groups [ Fig. 1(f) ].
The tracer analysis revealed no statistically significant difference in the basal EGP level among the groups [ Fig.  2(d) , white bars]. After 5 hours of fasting, 1.5 mU/kg/min of insulin with somatostatin and glucose was continuously infused for 2 hours [ Fig. 2(a) ]. The glucose infusion rate was fixed for the first 30 minutes and then adjusted to maintain euglycemia thereafter [ Fig. 2(b) ]. The blood glucose levels in the F and F+P+G groups were greater than that of the control group at t = 30 minutes [ Fig. 2(a) ]. The glucose infusion rate (GIR) during the clamp period was lower in these two groups [ Fig. 2 (b) and 2(c)]. This relatively low concentration of exogenous insulin induced full suppression of EGP in awake and nonrestrained mice, findings consistent with those from a previous report (27) , in the control group [ Fig. 2 (a-f) Z, n = 21; F, n = 7; P, n = 11; G, n = 6; F+P+G, n = 7. (g and h) Z, n = 6; F, n = 6; F+P+G, n = 5. Data presented as mean 6 standard error of the mean. *P , 0.05, **P , 0.01, ***P , 0.001 vs LacZ group. White squares indicate LacZ; black squares, FoxO1-T24A-S253A-S316A; black circles, PGC1a-S570A; white triangles, GSK3b-S9A; and white circles, all three Akt-substrate mutants expressed together. doi: 10.1210/en. https://academic.oup.com/endoresistance, represented by markedly lower GIR in the F group [ Fig. 2(c) ]. In contrast, the hepatic expression of PGC1a-S570A and GSK3b-S9A did not significantly affect EGP, Rd, or GIR [ Fig. 2(c-e) ]. Expression of all three Akt substrate mutants together induced effects on the basal insulin concentration [ Fig. 1(f) ], EGP [ Fig. 2(d) ], Rd [ Fig. 2(f) ], and GIR [ Fig. 2(c) ], similar to those produced by FoxO1 mutant expression alone, indicating that coexpression of PGC1a and GSK3b-S9A did not exert an additional effect beyond that of FoxO1-T24A-S253A-S316A expression.
Although the hepatic expression of FoxO1-T24A-S253A-S316A alone or with all three substrates together induced insulin resistance, no significant elevation of fasting blood glucose or basal EGP was observed, which might have resulted from the relatively short fasting time (5 hours). To elucidate whether a longer fasting time would significantly change the blood glucose or basal EGP, we performed basal tracer studies on the LacZ, FoxO1-T24A-S253A-S316A, and F+P+G groups. Even after a 24-hour fast, no significant elevation of either of these parameters was found [ Fig. 2 
(g) and 2(h)].
Hepatic adenoviral expression of FoxO1-ADA, another candidate for the constitutively active FoxO1 construct, reportedly induced unexpected blood glucose decreases (16) . This was reported to be due to FoxO1-induced Akt phosphorylation but was subsequently confirmed only in cultured cells (16, 28, 29) . To elucidate whether this phenomenon occurs in vivo, we analyzed liver samples from mice used in the basal tracer studies. Constitutive activation of hepatic FoxO1 significantly enhanced both Thr308 and Ser473 phosphorylation of Akt, indicating that the negative feedback loop exists even in vivo (Supplemental Fig. 2) .
Effects of hepatic expression of three Akt-substrate mutants on glucose-and lipid-regulatory gene expressions and hepatic glycogen and triglyceride contents
We analyzed the livers of mice after the clamp experiment for key enzymes reported to be involved in glucose metabolism. G6Pase expression was increased in the F, P, and F+P+G groups compared with the control group [ Fig. 3(a) ]. Moreover, G6Pase expression was significantly greater in the P group than in the F group. In contrast, PEPCK expression did not differ significantly among the groups [ Fig. 3(b) ]. GCK also did not differ significantly among the groups [ Fig. 3(c) ], although PDK4 expression was significantly elevated in the F, P, and F+P+G groups [ Fig. 3(e) ]. A recent study demonstrated that FoxO1 regulates the G6Pase/GCK ratio (30); thus, we analyzed this parameter and found this ratio to be significantly elevated in the F, P, and F+P+G groups [ Fig. 3(d) ]. Hepatic overexpression of GSK3b-S9A did not significantly affect G6Pase, PEPCK, GCK, the G6Pase/GCK ratio, or PDK4. We also quantitated the liver glycogen contents after the clamp experiments and found that glycogen was markedly decreased in response to GSK3b-S9A overexpression [ Fig. 3(f) ].
Expressions of key lipogenic genes, FAS and ACC, did not differ significantly among groups, except that GSK3b-S9A induced a significant reduction in FAS expression [ Fig. 3(g) and 3(h) ]. The inhibitory role of GSK3 on FAS was previously reported (31) . The hepatic triglyceride contents did not differ significantly among the five experimental groups [ Fig. 3(i) ]. Increased ATGL, a recently proposed mechanism by which FoxO1 might regulate hepatic lipid/glucose metabolism (32), was observed, not only in FoxO1-T24A-S253A-S316A, but also in the PGC1a-S570A and triple-expression groups [ Fig. 3(j) ].
Effects of three Akt substrates on gluconeogenic genes in cultured liver cells
We expressed the Akt substrate mutants in cultured liver cells to confirm their effects on glucose-regulatory genes. First, we infected H4IIE rat hepatoma cells with the three adenoviral vectors. The protein expression of all three constructs was more than five times the endogenous levels [ Fig. 4(a) ]. Both G6Pase and PEPCK were significantly reduced by insulin in the control group [Z group in Fig. 4(b) and 4(c) ]. The G6Pase levels were significantly increased in the F, P, and F+P+G groups, both with and without insulin [ Fig. 4(b) ]. PGC1a-S570A induced significantly greater G6Pase expression than did FoxO1-T24A-S253A-S316A. The PEPCK levels were not significantly altered in the insulin-negative state but were significantly elevated in the P, G, and F+P+G groups in the insulin-positive state [ Fig. 4(c) ]. PEPCK expression in the insulin-positive state was significantly greater in the P group than in the F group.
Finally, we tested the expression of the Akt substrate mutants in mouse primary hepatocytes. The protein expression of all three constructs was more than five times the endogenous levels [ Fig. 5(a) ]. Insulin significantly suppressed G6Pase Data presented as mean 6 standard error of the mean. Z, n = 21; F, n = 7; P, n = 11; G, n = 6; F+P+G, n = 7. *P , 0.05, **P , 0.01, ***P , 0.001 vs LacZ group; †P , 0.05 vs FoxO1-T24A-S253A-S316A group. doi: 10.1210/en. https://academic.oup.com/endomoderate effects of this construct on G6Pase and PEPCK result from the dose with which the cells were infected. However, the effects were significantly smaller, regardless of the MOI of FoxO1-T24A-S253A-S316A, than the strong effect induced by PGC1a-S570A (Supplemental Fig. 3 ). GSK3b-S9A significantly increased PEPCK, both with and without insulin [ Fig.  5(c) ]. The expression of FoxO1-T24A-S253A-S316A and PGC1a-S570A significantly suppressed GCK [ Fig. 5(d) ]. The G6Pase/GCK ratio was elevated by both FoxO1-T24A-S253A-S316A and PGC1a-S570A expression, but the effect of PGC1a-S570A was markedly stronger than that of FoxO1-T24A-S253A-S316A [ Fig. 5(e) ]. PDK4 expression was significantly increased in the F, P, and F+P+G groups [ Fig. 5(f) ].
The effect exerted on PDK4 by PGC1a-S570A was significantly greater in the insulin-negative state than that exerted by FoxO1-T24A-S253A-S316A.
Discussion
In the present study, we blocked hepatic insulin/Akt signaling at the level of three branch pathways downstream from Akt by overexpressing constitutively active Akt substrate-mutants and investigated which pathway has the most prominent role in glucose metabolism. We found that only blockade of the Akt/FoxO1 signaling pathway induced insulin resistance, with modest effects on gluconeogenic gene expression. The major advantage of our approach is that we performed a euglycemic clamp study without anesthesia or restriction, using arterial blood sampling, with physiological postprandial hyperinsulinemia, to simulate physiological postprandial conditions with minimal stress. Among the reported substrates of Akt, we chose the three most well-known substrates, which have been theoretically assumed to enhance glucose output from the liver and to be inhibited when phosphorylated by Akt at specific Ser/Thr (2) and (+) groups, multiple comparisons were performed just among the viral groups because Tukey test did not detect a statistically significant difference between the insulin (2) and (+) in any of the adenovirus-infected groups. doi: 10.1210/en. https://academic.oup.com/endoresidues. The Akt-unresponsive mutants we used in the present study are the same construct previously used for overexpression (4, (33) (34) (35) (36) (37) (38) or knock-in (20, 22, 39) studies, in which they served as constitutively active mutants. A major limitation of our approach was the difficulty in matching the protein expression levels among the different proteins. We simply matched the titers of adenoviruses to avoid nonspecific effects due to viral infection, resulting in protein expression levels several fold greater than the endogenous levels, which, although not completely matched, were comparable to each other. Despite this limitation, we found that overexpression of FoxO1-T24A-S253A-S316A in the liver induces insulin resistance via the blunted suppression of endogenous glucose production and peripheral glucose disappearance. In contrast, overexpression of PGC1a-S570A or of GSK3b-S9A changed neither hepatic nor peripheral insulin sensitivity. Recently, two reports have shown that even in hepatic insulin receptor (IR)-null mice [liver-specific insulin receptor knockout (LIRKO) mice], hepatic codeletion of FoxO1 [liver-specific insulin receptor/FoxO1 double knockout (LIRFKO)] reverses insulin resistance and the impaired glucose tolerance in LIRKO mice (40, 41) . LIRFKO mice have no IRs but presumably have intact PGC1a and GSK3b in the liver, which would not be suppressed by insulin stimulation because of IR deletion. However, insulin sensitivity in LIRFKO is not distinguishable from that in wild-type mice. Our findings, along with the phenotypes of LIRFKO mice, suggest that the Akt/FoxO1 pathway predominates over the Akt/PGC1a or Akt/GSK3b pathway when transducing insulin's suppressive effect on glucose output from the liver.
Studies of hepatic constitutively active FoxO1 overexpression have thus far obtained contradictory results. Adenoviral hepatic FoxO1-T24A-S253A-S316A expression exacerbated hyperglycemia in diabetic mice (35) and liver-specific FoxO1-T24A-S253A-S316A transgenic mice showed fasting hyperglycemia or hyperinsulinemia (33) . However, liver-specific FoxO1-ADA adenoviral expression, in which Ser256 (corresponds to mouse Ser253) of FoxO1 is substituted not by alanine but by aspartate, induced hypoglycemia (16) . We adenovirally expressed FoxO1-T24A-S253A-S316A and found that this mutant induces insulin resistance in regular C57Bl/6 mice, which is basically consistent with the observation in FoxO1-T24A-S253A-S316A transgenic mice but inconsistent with those from FoxO1-ADA adenoviral expression studies. Thus, the discrepancy might be explained by the difference in the mutation at Ser256, which is responsible for DNA binding. In cultured cells, although both FoxO1-T24A-S253A-S316A and FoxO1-ADA stay in the nucleus, only the former mutant showed DNA-binding activity (34) . The results from the present study showed that postnatal constitutive activation of FoxO1 with DNA-binding activity induces insulin resistance, similar to that observed in a transgenic model (33) .
The 1-week expression of constitutively active FoxO1 solely in the liver induced not only hepatic but also peripheral insulin resistance, as indicated by a decrease in Rd. This observation is consistent with those in LIRFKO mice, in which deletion of FoxO1 reversed not only the hepatic but also the peripheral insulin resistance induced by IR deletion (41) . Furthermore, hepatic Akt2 deletion induced not only hepatic but also peripheral insulin resistance (22) . The mechanism underlying the greater weight gain in response to FoxO1-T24A-S253A-S316A expression and increased fat mass with triple expression is unclear; however, the hyperglycemia displayed by these two groups allowed us to speculate that the hyperglycemia induced greater glucose uptake by adipose tissue, resulting in an increased fat mass and body weight. The chronic hyperinsulinemia and body weight gain induced by hepatic FoxO1-T24A-S253A-S316A expression might have induced secondary insulin resistance in peripheral tissues, the confirmation of which requires further study.
Hepatic GSK3b-S9A expression significantly lowered hepatic glycogen without changing insulin sensitivity. Liver-specific GSK3b-null mice and systemic GSK3a-S21A/GSK3b-S9A double knock-in mice showed no change in either insulin sensitivity or hepatic glycogen in the fed state (20, 21) . The double knock-in mice unexpectedly showed an increase in hepatic glycogen in the fasted state (20) . Considering these findings, the decrease in hepatic glycogen in our study might be attributable to superphysiological expression of the GSK3b mutant. Our results also suggest that even the forced decrease in hepatic glycogen did not affect insulin sensitivity. This is also consistent with the findings obtained with LIRFKO mice, which show hepatic glycogen reductions but not insulin resistance (40) .
The lack of a significant effect on insulin sensitivity by hepatic PGC1a-S570A overexpression is unexpected. We verified the function of this mutant in H4IIE cells and mouse primary hepatocytes and confirmed the marked increases in G6Pase and PEPCK. G6Pase was also increased in the mouse liver by this construct. Arterial blood sampling from the catheter should have a less stressful effect on the animal compared with tail sampling and would, thus, be expected to induce lower secretion of counterregulatory hormones, whose signaling mechanisms involve PGC1a. Also, other regulatory mechanisms of PGC1a such as phosphorylation at residues other than Ser570 and acetylation/deacetylation have been reported. The construct we used is only resistant to Ser570 phosphorylation, and other regulatory mechanisms would not be disturbed. Therefore, our present results suggest that, at a minimum, the phosphorylation of PGC1a at Ser570 by Akt has less influence on insulin sensitivity than the Akt/FoxO1 pathway.
Another unexpected observation is that no significant change was found in either fasting blood glucose or basal glucose production. Hepatic FoxO1-T24A-S253A-S316A overexpression induced significant hyperinsulinemia, which would presumably be sufficient to compensate for the insulin resistance and thereby avoid fasting hyperglycemia. This is in contrast to the situation in the FoxO1-T24A-S253A-S316A transgenic mice, which reportedly showed fasting hyperglycemia (33) . This discrepancy might be explained by the time course of overactivation. Also, other Akt substrates such as SIK2 (6), Clk2 (8), ERRg (7), and InsP 3 R (9) are reportedly involved in glucose metabolism and might have compensatory actions. Moreover, the postnatal knockdown of liver IR resulted in hyperinsulinemia without elevation of fasting blood glucose (41), findings similar to those from our present study. Taking these observations together, we speculate that postnatal short-term inhibition of insulin signaling might be sufficiently compensated for by pancreatic insulin secretion to avoid fasting hyperglycemia.
The mechanisms downstream from Akt/FoxO1 functioning to regulate hepatic glycose output have not been fully clarified; however, G6Pase and PEPCK are generally thought to be significantly involved. In the present study, we confirmed that these key gluconeogenic genes are modulated by activation of FoxO1 and PGC1a. Compared with the modest effects on gluconeogenic genes induced by FoxO1-T24A-S253A-S316A, the effects of PGC1a-S570A were markedly stronger in both mouse liver and cultured cells. Despite these marked upregulations of gluconeogenic genes induced by PGC1a-S570A, no insulin resistance was induced by this construct, indicating that the insulin resistance induced by hepatic activation of FoxO1 might involve mechanisms other than these gene upregulations.
According to our data search, the regulatory role of FoxO1 in PEPCK expression has been controversial. Both G6Pase and PEPCK were increased in the FoxO1-T24A-S253A-S316A transgenic mouse liver (33) . Adenoviral hepatic expression of FoxO1-ADA increased G6Pase; however, the effects on PEPCK have not been reported (16) . In liver-specific FoxO1-null mice, hepatic G6Pase was decreased, with no change in PEPCK (15) . When the hepatocytes from this knockout mouse were cultured, both G6Pase and PEPCK levels were suppressed (15), consistent with our present observations. Deletion of Akt2 in the liver induced insulin resistance without significantly changing either G6Pase or PEPCK (22) . Increased G6Pase and decreased GCK with no change in PEPCK was reported in FoxO1/3/4 triple-null mice (30) , also consistent with our present observations.
In mouse primary hepatocytes, GCK expression was markedly decreased by constitutively active FoxO1 and PGC1a. The G6Pase/GCK ratio was significantly increased by constitutively active FoxO1 and PGC1a in both primary hepatocytes and the liver. This change induced by FoxO1 is consistent with the reported increase in hepatic GCK and the decrease in the G6Pase/GCK ratio in FoxO1/ 3/4 triple-null mice, although the underlying mechanism remains unclear (30) . PDK4, a negative regulator of glycolysis, is downregulated by the insulin/Akt pathway and upregulated by FoxO1 and PGC1a (42, 43) . Consistently, our results showed that constitutive activation of FoxO1 and PGC1a enhanced PDK4 expression in both the mouse liver and primary hepatocytes. However, the effect of PGC1a was similar to that of FoxO1, indicating that the insulin resistance induced by hepatic activation of FoxO1 is not fully explained by PDK4 expression. Upregulation of ATGL was observed in response to FoxO1-T24A-S253A-S316A overexpression, consistent with the transgenic model (32) . However, this change was also observed in the PGC1a-S570A expression group, which did not show insulin resistance, implying that the change in ATGL might not fully explain the insulin resistance induced by constitutively active FoxO1.
In conclusion, among the three Akt substrates we investigated, FoxO1 played the major role downstream from Akt in transducing insulin's regulatory effect on glucose metabolism. The underlying mechanism might involve expressional regulation of G6Pase, the G6Pase/ GCK ratio, PDK4, and ATGL. However, the regulation of key gluconeogenic genes by FoxO1 did not fully explain the observed insulin resistance induced by hepatic constitutive activation of FoxO1, suggesting other mechanisms downstream from the insulin/Akt/FoxO1 pathway to be involved in regulating glucose metabolism. Table   Peptide 
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